The Success of Smoking Cessation Treatments:The Gulhane Experience

Yakup ARSLAN, (Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Nesrin ÖCAL, (Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Ahmet ÇAĞIN, (Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Deniz DOGAN, (Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Cantürk TAŞÇI (Sağlık Bilimleri Üniversitesi, Gülhane Eğitim ve Araştırma Hastanesi, Göğüs Hastalıkları Anabilim Dalı, Ankara, Türkiye)
Addicta: The Turkish Journal on Addictions
12 0
Yıl: 2021 Cilt: 8 Sayı: 1 Sayfa Aralığı: 8 - 15 Metin Dili: İngilizce DOI: 10.5152/ADDICTA.2021.21041 İndeks Tarihi: 20-11-2021

The Success of Smoking Cessation Treatments:The Gulhane Experience

Öz:
This study aimed to evaluate the success and factors that affected the success of smoking cessation treatments adopted in the Gulhane Smoking Cessation Polyclinic (SCP). The smokers admitted to SCP from January 1, 2018, to July 15, 2019, were included in the study. The participants were treated with varenicline or nicotine replacement therapy (NRT) combined with cognitive behavioral therapy (CBT). The number of all participants was 598, and 196 (32.8%) of them quitted smoking successfully. The varenicline group (n=264) had significantly higher number and percentage of participants who successfully quit smoking than the NRT group (n=334), which accounted for 113 (42.8%) and 83 (24.9%), respectively (p<0.001). The highest smoking cessation rate was detected in the group with low Fagerström Test for Nicotine Dependence (FTND) at 79.5% (p<0.001). Participants without comorbidity had higher smoking cessation rates than others (p=0.002). The mean numbers of follow-up visits were higher in the successfully quit group with a mean number of 4.2 (p<0.001). CBT combined with varenicline was found to be more successful than CBT combined with NRT in smoking cessation. The reliability of varenicline, low FTND level, absence of comorbidity, and increased numbers follow-up visits were found to be contributing factors to this success.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Diğer Erişim Türü: Erişime Açık
  • Akkaya, A., Ozturk, O., Cobanoglu, H., Bircan, HA., Simsek, S., & Sahin U. (2006). Evaluation of patients followed up in a cigarette cessation clinic. Respirology, 11(3), 311-316.
  • Arguder, E., Karalezli, A., Hezer, H., Kılıc, H., Er, M., Hasanoglu, H. C., & Demir, P. (2013). Factors Affecting the Success of Smoking Cessation. Turkish Thoracic Journal, 14, 81-87.
  • Arslan, Y., Ocal, N., Dogan, D., Cagın, A., Tascı, C., & Sarı, O. (2021). The awareness of chronic obstructive pulmonary disease among smokers admitting to pulmonary medicine outpatient clinic: Single center experience. Gulhane Medical Journal, 63, 59-67.
  • Aytemur, Solak, Z., Gunduz, Telli, C., & Erdinc, E. (2003). Results of smoking cessation treatment. Toraks Dergisi, 4(1), 73-77.
  • Cahill, K., Lindson-Hawley, N., Thomas, K. H., Fanshawe, T. R., & Lancaster, T. (2016). Nicotine receptor partial agonists for smoking cessation. The Cochrane Database of Systematic Reviews, 5, CD006103.
  • Calikoglu, EO., & Koycegiz, E. (2019). Tobacco Control Policies in Turkey in Terms of MPOWER. The Eurasian Journal of Medicine, 51(1), 80-84.
  • Can, G., Oztuna, F., & Ozlu, T. (2004). The evaluation of outpatient smoking cessation clinic results. Tüberküloz ve Toraks, 52(1), 69-74.
  • Celik, I., Yuce, D., Hayran, M., Erman, M., Kılıckap, S., Buzgan, T., Irmak, H., Tosun, N., Tuncer, M., & Akdağ, R. (2015). Nationwide smoking cessation treatment support program-Turkey project. Health Policy, 1, 50-56.
  • Demir, T., Tutluoglu, B., Koc, N., & Bilgin, L. (2004). Oneyear follow up results of smoking cessation outpatient clinic. Tüberküloz ve Toraks, 52(1), 63-8.
  • Dubray, J., Schwartz, R., Chaiton, M., O’Connor, S., & Cohen, J. E. (2015). The effect of MPOWER on smoking prevalence. Tobacco Control, 24(6), 540-542.
  • Ebbert, J. O., Hughes, J. R., West, R. J., Rennard, I. S., Russ, C., Macrae, T. D., Treadow, J., You, C. R., Dutro, M. P., & Park, P. W. (2015). Effect of varenicline on smoking cessation through smoking reduction: a randomized clinical trial. JAMA, 313(7), 687-694.
  • Fiore, M. C., Jaén, C. R., Baker, T. B., Bailey, W. C., Benowitz, N. L., & Curry, S. J. (2008). Treating tobacco use and dependence: 2008 Update U.S. Public Health Service Clinical Practice Guideline executive summary. Respiratory Care, 53(9), 1217-1222.
  • GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. (2018). Global, regional, and national incidence, prevalence, and years lived with disabi lity for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet (London, England), 392(10159), 1789-1858.
  • Górecka, D., Bednarek, M., Nowiński, A., Puścińska, E., Goljan-Geremek, A., & Zieliński, J. (2003). Diagnosis of airflow limitation combined with smoking cessation advice increases stop smoking rate. Chest, 123, 1916-1923.
  • Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerström, K. O. (1991). The Fagerström Test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86(9), 1119-1127.
  • Janson, C., Kunzli, N., deMarco, R., Chinn, S., Jarvis, D., Svanes, C., Heinrich, J., Jõgi, R., Gislason, T., Sunyer, J., Liebrich, U. A., Antó, J. M., Cerveri, I., Kerhof, M., Leynaert, B., Luczynska, C., Neukirch, F., Vermeire, R., Wjst, M., & Burney, P. (2006). Changes in active and passive smoking in European Community Respiratory Health Survey. European Respiratory Journal, 27, 517-524.
  • Jorenby, D. E., Leischow, S. J., Nides, M. A., Rennard, S. I., Johnston, J. A., Hughes, A. R., Smith, S. S., M. L., Muramoto, M. L., Daughton, D. M., Doan, K., Fiore, M. C., & Baker, T. B. (1999). A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. The New England Journal of Medicine, 340, 685-691.
  • Kaleta, D., Koziel, A., & Miśkiewicz, P. (2009). MPOWER-strategy for fighting the global tobacco epidemic. Medicine Partners, 60(2), 145- 149.
  • Kenford, S. L., Fiore, M. C., Jorenby, D. E., Smith, S. S., Wetter, D., & Baker, T. B. (1994). Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA, 271, 589-594.
  • Kennedy, D. T., Giles, J. T., Chang, Z. G., Small, R. E., & Edwards, J. H. (2002). Results of a smoking cessation clinic in community pharmacy practice. Journal of the American Pharmacists Association, 42(1), 51-6.
  • Kocak, N. D., Eren, A., Boga, S., Akturk, U. A., Ozturk, U. A., Arınc, S., & Sengul, A. (2015). Relapse Rate and Factors Related to Relapse in a 1-Year Follow-Up of Subjects Participating in a Smoking Cessation Program. Respiratory Care, 60(12), 1796-1803.
  • Marakoglu, K., Kargın, N. C., Ucar R. M., & Kızmaz, M. (2017). Evaluation of pharmacologic therapies accompanied by behavioral therapy on smoking cessation success: a prospective cohort study in Turkey. Psychiatry and Clinical Psychopharmacology, 27(3), 221-227.
  • Markou, A. (2008). Neurobiology of nicotine dependence. Philosophical transactions of the Royal Society of London Series B, Biological Sciences, 363(1507), 3159-3168.
  • Monso, E., Campbell, J., Tonnosen, P., Gustavsson, G., & Morera, J. (2001). Sociodemographic predictors of success in smoking intervention. Tobacco Control, 10, 165-169.
  • Oztuna, F., Can, G., Ayık, S., Ozlu, T., & Yılmaz, I. (2013). Long-Term Results of Smoking Cessation Therapy. Turkiye Klinikleri Journal of Medical Sciences, 33(5), 1201-1208.
  • Ozturk, O. (2019). A smoking cessation clinic operating within a family health center and its working practices. Turkish Journal of Public Health, 17(1), 100-101.
  • Peacock, A., Leung, J., Larney, S., Colledge, S., Hickman, M., Rehm, J., Giovino, GA., West, R., Hall, W., Griffiths, P., Ali, R., Gowing, L., Marsden, J., Ferrari, A.J., Gerebely, J., Farrell, M., & Degenhardt, L. (2018). Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction (Abingdon, England), 113(10), 1905-1926.
  • Roche, D. J., Bujarski, S., Moallem, N. R., Guzman, I., Shapiro, J. R., & Ray, L. A. (2014). Predictors of smoking lapse in a human laboratory paradigm. Psychopharmacology, 231(14), 2889-2897.
  • Sahbaz, S., Kılınc, O., Gunay, T., & Ceylan, E. (2007). The Effects of Smoking Properties and Demographic Properties on the Results of Smoking Cessation Therapy. Turkish Thoracic Journal, 8, 110-114.
  • Shields, P. G., Herbst, R. S., Arenberg, D., Benowitz, N. L., Bierut, L., Luckart, J. B., Cinciripini, P., Collins, B., David, S., Davis, J., Hitsman, B., Hyland, A., Lang, M., Leischow, S., Park, E. R., Purcell, W. T., Selzle, J., Silber, A., Spencer, S., Tanvetyanon, T., Tiep, B., Tindle, H. A., Seeley, R. T., Urbanic, J., Hooper, M. W., Weksler, B., Whitlock, C. W., Wood, D. E., Burns, J., & Scavone, J. (2016). Smoking Cessation, Version1 NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 14(11), 1430-1468. Tobacco Addiction Treatment and Education Units Regulation. (2011)., No: 4207.
  • Ucar, E., Araz, O., Yılmaz, N., Akgun, M., Meral, M., Kaynar, H., & Saglam, L. (2014). Effectiveness of pharmacologic therapies on smoking cessation success: three years results of a smoking cessation clinic. Multidisciplinary Respiratory Medicine, 1, 9.
  • Uzaslan, E. K., Ozyardımcı, N., Karadag, M., & Yuksel, E. G. (2000). The physician’s intervention in smoking cessation: results of the 5 years of smoking cessation clinic. Annals of Medical and Health Science Research, 9(1), 63-69.
  • Wood-Baker, R. (2002). Outcome of a smoking cessation programme run in a routine hospital setting. Internal Medicine Journal, 32(1-2), 24-28.
  • Yasar, Z., Kurt, O., Talay, F., & Kargı, A. (2014). One-Year Follow-up Results of Smoking Cessation Outpatient Clinic: Factors Affecting the Cessation of Smoking. Eurasian Journal of Pulmonology, 16, 99-104.
APA ARSLAN Y, ocal n, ÇAĞIN A, Doğan D, TASÇI C (2021). The Success of Smoking Cessation Treatments:The Gulhane Experience. , 8 - 15. 10.5152/ADDICTA.2021.21041
Chicago ARSLAN YAKUP,ocal nesrin,ÇAĞIN Ahmet,Doğan Deniz,TASÇI CANTÜRK The Success of Smoking Cessation Treatments:The Gulhane Experience. (2021): 8 - 15. 10.5152/ADDICTA.2021.21041
MLA ARSLAN YAKUP,ocal nesrin,ÇAĞIN Ahmet,Doğan Deniz,TASÇI CANTÜRK The Success of Smoking Cessation Treatments:The Gulhane Experience. , 2021, ss.8 - 15. 10.5152/ADDICTA.2021.21041
AMA ARSLAN Y,ocal n,ÇAĞIN A,Doğan D,TASÇI C The Success of Smoking Cessation Treatments:The Gulhane Experience. . 2021; 8 - 15. 10.5152/ADDICTA.2021.21041
Vancouver ARSLAN Y,ocal n,ÇAĞIN A,Doğan D,TASÇI C The Success of Smoking Cessation Treatments:The Gulhane Experience. . 2021; 8 - 15. 10.5152/ADDICTA.2021.21041
IEEE ARSLAN Y,ocal n,ÇAĞIN A,Doğan D,TASÇI C "The Success of Smoking Cessation Treatments:The Gulhane Experience." , ss.8 - 15, 2021. 10.5152/ADDICTA.2021.21041
ISNAD ARSLAN, YAKUP vd. "The Success of Smoking Cessation Treatments:The Gulhane Experience". (2021), 8-15. https://doi.org/10.5152/ADDICTA.2021.21041
APA ARSLAN Y, ocal n, ÇAĞIN A, Doğan D, TASÇI C (2021). The Success of Smoking Cessation Treatments:The Gulhane Experience. Addicta: The Turkish Journal on Addictions, 8(1), 8 - 15. 10.5152/ADDICTA.2021.21041
Chicago ARSLAN YAKUP,ocal nesrin,ÇAĞIN Ahmet,Doğan Deniz,TASÇI CANTÜRK The Success of Smoking Cessation Treatments:The Gulhane Experience. Addicta: The Turkish Journal on Addictions 8, no.1 (2021): 8 - 15. 10.5152/ADDICTA.2021.21041
MLA ARSLAN YAKUP,ocal nesrin,ÇAĞIN Ahmet,Doğan Deniz,TASÇI CANTÜRK The Success of Smoking Cessation Treatments:The Gulhane Experience. Addicta: The Turkish Journal on Addictions, vol.8, no.1, 2021, ss.8 - 15. 10.5152/ADDICTA.2021.21041
AMA ARSLAN Y,ocal n,ÇAĞIN A,Doğan D,TASÇI C The Success of Smoking Cessation Treatments:The Gulhane Experience. Addicta: The Turkish Journal on Addictions. 2021; 8(1): 8 - 15. 10.5152/ADDICTA.2021.21041
Vancouver ARSLAN Y,ocal n,ÇAĞIN A,Doğan D,TASÇI C The Success of Smoking Cessation Treatments:The Gulhane Experience. Addicta: The Turkish Journal on Addictions. 2021; 8(1): 8 - 15. 10.5152/ADDICTA.2021.21041
IEEE ARSLAN Y,ocal n,ÇAĞIN A,Doğan D,TASÇI C "The Success of Smoking Cessation Treatments:The Gulhane Experience." Addicta: The Turkish Journal on Addictions, 8, ss.8 - 15, 2021. 10.5152/ADDICTA.2021.21041
ISNAD ARSLAN, YAKUP vd. "The Success of Smoking Cessation Treatments:The Gulhane Experience". Addicta: The Turkish Journal on Addictions 8/1 (2021), 8-15. https://doi.org/10.5152/ADDICTA.2021.21041
Sayfa Oluşturulma Tarihi
23-04-2024 20:12

İLETİŞİM

TÜBİTAK ULAKBİM TR Dizin

Yüzüncüyıl, İşçi Blokları Mahallesi

Muhsin Yazıcıoğlu Caddesi No:51/C

06530 Çankaya / ANKARA +90 (312) 298 92 00

trdizin@tubitak.gov.tr

TÜBİTAK ULAKBİM Ulusal Akademik Ağ ve Bilgi Merkezi Cahit Arf Bilgi Merkezi © Tüm Hakları Saklıdır. Gizlilik Politikası Kullanım Şartları